CN1741821B - 用于癌症治疗的组合物 - Google Patents

用于癌症治疗的组合物 Download PDF

Info

Publication number
CN1741821B
CN1741821B CN2003801078446A CN200380107844A CN1741821B CN 1741821 B CN1741821 B CN 1741821B CN 2003801078446 A CN2003801078446 A CN 2003801078446A CN 200380107844 A CN200380107844 A CN 200380107844A CN 1741821 B CN1741821 B CN 1741821B
Authority
CN
China
Prior art keywords
cell
glycogen
reagent
purposes
expression
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CN2003801078446A
Other languages
English (en)
Chinese (zh)
Other versions
CN1741821A (zh
Inventor
B·多伊伦
S·波纳尔
A·张
E·苏
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Engene Inc
Original Assignee
Engene Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Engene Inc filed Critical Engene Inc
Publication of CN1741821A publication Critical patent/CN1741821A/zh
Application granted granted Critical
Publication of CN1741821B publication Critical patent/CN1741821B/zh
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/45—Transferases (2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/47—Hydrolases (3) acting on glycosyl compounds (3.2), e.g. cellulases, lactases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/25—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving enzymes not classifiable in groups C12Q1/26 - C12Q1/66
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/34—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving hydrolase
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y301/00—Hydrolases acting on ester bonds (3.1)
    • C12Y301/03—Phosphoric monoester hydrolases (3.1.3)
    • C12Y301/03016—Phosphoprotein phosphatase (3.1.3.16), i.e. calcineurin
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5011—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing antineoplastic activity
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/502—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects
    • G01N33/5023—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects on expression patterns
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10341—Use of virus, viral particle or viral elements as a vector
    • C12N2710/10343—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Microbiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Physics & Mathematics (AREA)
  • Hematology (AREA)
  • Analytical Chemistry (AREA)
  • Epidemiology (AREA)
  • Urology & Nephrology (AREA)
  • Biophysics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Cell Biology (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Plant Pathology (AREA)
CN2003801078446A 2002-10-29 2003-10-29 用于癌症治疗的组合物 Expired - Fee Related CN1741821B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US42236502P 2002-10-29 2002-10-29
US60/422,365 2002-10-29
PCT/IB2003/005562 WO2004039412A2 (en) 2002-10-29 2003-10-29 Compositions for cancer treatment

Publications (2)

Publication Number Publication Date
CN1741821A CN1741821A (zh) 2006-03-01
CN1741821B true CN1741821B (zh) 2011-08-10

Family

ID=32230344

Family Applications (1)

Application Number Title Priority Date Filing Date
CN2003801078446A Expired - Fee Related CN1741821B (zh) 2002-10-29 2003-10-29 用于癌症治疗的组合物

Country Status (7)

Country Link
US (2) US20050202559A1 (enExample)
EP (1) EP1556088A2 (enExample)
JP (1) JP2006508939A (enExample)
CN (1) CN1741821B (enExample)
AU (1) AU2003282306A1 (enExample)
CA (1) CA2503422A1 (enExample)
WO (1) WO2004039412A2 (enExample)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7381413B1 (en) * 1998-04-17 2008-06-03 University Of Vermont And State Agricultural College Methods and products related to metabolic interactions in disease
AU2004248187A1 (en) * 2003-06-12 2004-12-23 University Of Colorado System Technology Systems and methods for treating human inflammatory and proliferative diseases and wounds, with fatty acid metabolism inhibitors and/or glycolytic inhibitors
WO2005044275A1 (en) * 2003-11-06 2005-05-19 Cyclacel Limited Use
US7510710B2 (en) 2004-01-08 2009-03-31 The Regents Of The University Of Colorado Compositions of UCP inhibitors, Fas antibody, a fatty acid metabolism inhibitor and/or a glucose metabolism inhibitor
WO2006066408A1 (en) * 2004-12-21 2006-06-29 Viventia Biotech Inc. Cancer specific antibody and cell surface proteins
AU2006239896A1 (en) * 2005-04-28 2006-11-02 The Regents Of The University Of Colorado Therapeutic bifunctional compounds
WO2006118821A2 (en) * 2005-05-02 2006-11-09 The Regents Of The University Of Colorado Systems and methods for treating human inflammatory and proliferative diseases, with a combination of compounds, or a bifunctional compound,that provides fatty acid metabolism and glycolysis inhibition
US20090232735A1 (en) * 2005-08-24 2009-09-17 Cedars-Sinai Medical Center Use of fructose-based therapies for the treatment of cancer
JPWO2007037533A1 (ja) * 2005-09-30 2009-04-16 リンク・ジェノミクス株式会社 Ｐｐｐ１ｒ３ｄ遺伝子の治療的又は診断的用途
US20090011060A1 (en) * 2007-07-06 2009-01-08 Peter Koepke Campsiandra angustifolia extract and methods of extracting and using such extract
US7879369B2 (en) 2007-09-18 2011-02-01 Selvamedica, Llc Combretum laurifolium Mart. extract and methods of extracting and using such extract
WO2009105230A2 (en) * 2008-02-21 2009-08-27 The Regents Of The University Of Colorado Methods for treating cancer using combination therapy
WO2009140624A2 (en) 2008-05-16 2009-11-19 Takeda San Diego, Inc. Glucokinase activators
US9073985B2 (en) 2008-07-14 2015-07-07 The Regents Of The University Of Colorado, A Body Corporate Methods and products for treating proliferative diseases
US20120322150A1 (en) * 2009-07-17 2012-12-20 Carnegie Institution Of Washington Mechanism and Method for Regulating Glycogen Synthase Kinase 3 (GSK3)-Related Kinases
US8178307B2 (en) * 2009-09-02 2012-05-15 National Tsing Hua University Methods and compositions for detection of lethal cell and uses thereof
CN103037690B (zh) * 2010-03-24 2016-04-27 俄亥俄州立大学 用于葡萄糖转运抑制的组合物和方法
US20140106004A1 (en) * 2012-10-12 2014-04-17 Bing Lou Wong Hemoglobin-based oxygen carrier-containing pharmaceutical composition for cancer targeting treatment and prevention of cancer recurrence
JP5804389B2 (ja) * 2013-01-11 2015-11-04 国立大学法人東北大学 運動に応答して筋肉細胞において発現変動するタンパク質及びそれらの受容体、それらをコードする遺伝子、並びにそれらを用いたスクリーニング方法
SI3054996T1 (sl) 2013-10-07 2023-11-30 Igl Pharma, Inc. Postopek za pripravo terapevtskih sredstev za kosti visoke čistote
US9580699B2 (en) 2014-04-17 2017-02-28 University of Pittsburgh—of the Commonwealth System of Higher Education TRPV1 modulatory gene product that affects TRPV1-specific pain behavioral responses identified in a functional screen of an HSV-based cDNA library
US11318163B2 (en) 2015-02-18 2022-05-03 Enlivex Therapeutics Ltd Combination immune therapy and cytokine control therapy for cancer treatment
US11596652B2 (en) 2015-02-18 2023-03-07 Enlivex Therapeutics R&D Ltd Early apoptotic cells for use in treating sepsis
IL303543A (en) 2015-02-18 2023-08-01 Enlivex Therapeutics Rdo Ltd Combination immune therapy and cytokine control therapy for cancer treatment
US11497767B2 (en) 2015-02-18 2022-11-15 Enlivex Therapeutics R&D Ltd Combination immune therapy and cytokine control therapy for cancer treatment
US11000548B2 (en) 2015-02-18 2021-05-11 Enlivex Therapeutics Ltd Combination immune therapy and cytokine control therapy for cancer treatment
US11304976B2 (en) 2015-02-18 2022-04-19 Enlivex Therapeutics Ltd Combination immune therapy and cytokine control therapy for cancer treatment
CN113106053A (zh) 2015-04-21 2021-07-13 恩立夫克治疗有限责任公司 治疗性汇集的血液凋亡细胞制剂与其用途
EP3416661A4 (en) 2016-02-18 2020-03-04 Enlivex Therapeutics Ltd. COMBINATION OF IMMUNOTHERAPY AND CYTOKINE CONTROL THERAPY FOR THE TREATMENT OF CANCER
WO2018222926A1 (en) 2017-05-31 2018-12-06 Ultragenyx Pharmaceutical Inc. Therapeutics for glycogen storage disease type iii
CN110051841B (zh) * 2019-05-28 2021-02-02 北京大学 Nat10抑制剂在制备用于抑制hif表达的药物中的应用
JP7743536B2 (ja) * 2021-04-14 2025-09-24 ヴェンタナ メディカル システムズ， インク． 免疫組織化学（ｉｈｃ）の合成画像への組織化学的染色画像の変換
CN118924748A (zh) * 2024-07-19 2024-11-12 广州百吉生物制药有限公司 一种诱导实体肿瘤分化的药物及其应用

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001052862A1 (en) * 2000-01-19 2001-07-26 Isis Pharmaceuticals, Inc. Antisense modulation of glycogen synthase kinase 3 beta expression

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH08198758A (ja) * 1995-01-24 1996-08-06 Aomori Pref Gov グリコーゲンの癌予防剤としての用法
US5939284A (en) * 1996-12-05 1999-08-17 Smithkline Beecham Corporation Protein phosphatase 1 binding protein, R5
US6043091A (en) * 1999-07-19 2000-03-28 Isis Pharmaceuticals Inc. Antisense modulation of liver glycogen phosphorylase expression
US20030166592A1 (en) * 1999-07-19 2003-09-04 Monia Brett P. Antisense modulation of liver glycogen phosphorylase expression
ATE424457T1 (de) * 2000-01-13 2009-03-15 Genentech Inc Menschliche stra6 polypeptide
AU783615B2 (en) * 2000-05-11 2005-11-17 Consejo Superior De Investigaciones Cientificas Heterocyclic inhibitors of glycogen synthase kinase GSK-3
IL144507A0 (en) * 2000-07-31 2002-05-23 Pfizer Prod Inc Use of glycogen phosphorylase inhibitors to inhibit tumor growth
US20040180845A1 (en) * 2003-03-13 2004-09-16 Newgard Christopher B. Methods and compositions for modulating glycogen synthesis and breakdown

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001052862A1 (en) * 2000-01-19 2001-07-26 Isis Pharmaceuticals, Inc. Antisense modulation of glycogen synthase kinase 3 beta expression

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
HAL K.BERMAN.OVEREXPRESSION OF PROTEIN TARGETING TOGLYCOGEN (PTG) IN RAT HEPATOCYTES CAUSESPROFOUND ACTIVATION OF GLYCOGEN SYNTHESISINDEPENDENT OF NORMAL HORMONE- ANDSUBSTRATE-MEDIATED REGULATORY MECHANISMS.THE JOURNAL OF BIOLOGICAL CHEMISTRY273 41.1998,273(41),26421-26425，具体参见其摘要.
HAL K.BERMAN.OVEREXPRESSION OF PROTEIN TARGETING TOGLYCOGEN (PTG) IN RAT HEPATOCYTES CAUSESPROFOUND ACTIVATION OF GLYCOGEN SYNTHESISINDEPENDENT OF NORMAL HORMONE- ANDSUBSTRATE-MEDIATED REGULATORY MECHANISMS.THE JOURNAL OF BIOLOGICAL CHEMISTRY273 41.1998,273(41),26421-26425,具体参见其摘要. *

Also Published As

Publication number Publication date
EP1556088A2 (en) 2005-07-27
CN1741821A (zh) 2006-03-01
US20050202559A1 (en) 2005-09-15
WO2004039412A3 (en) 2004-11-04
JP2006508939A (ja) 2006-03-16
WO2004039412A2 (en) 2004-05-13
AU2003282306A1 (en) 2004-05-25
US20090041740A1 (en) 2009-02-12
CA2503422A1 (en) 2004-05-13

Similar Documents

Publication Publication Date Title
CN1741821B (zh) 用于癌症治疗的组合物
JP2006508939A5 (enExample)
Yenari et al. Antiapoptotic and anti‐inflammatory mechanisms of heat‐shock protein protection
Zlokovic et al. Cellular and molecular neurosurgery: Pathways from concept to reality-Part II: Vector systems and delivery methodologies for gene therapy of the central nervous system
Schiffelers et al. Effects of treatment with small interfering RNA on joint inflammation in mice with collagen‐induced arthritis
Biglari et al. Effects of ectopic decorin in modulating intracranial glioma progression in vivo, in a rat syngeneic model
Navarro et al. Cancer suicide gene therapy: a patent review
Riley et al. Adenovirus–mediated retinoblastoma gene therapy suppresses spontaneous pituitary melanotroph tumors in Rb+/− mice
Wang et al. Hepatic regulator of G protein signaling 5 ameliorates nonalcoholic fatty liver disease by suppressing transforming growth factor beta–activated kinase 1–c‐Jun‐N‐terminal kinase/p38 signaling
NZ787373A (en) Novel crispr enzymes and systems
SA516370442B1 (ar) صورة متغيرة من aav ، وتركيبات وطرق واستخدامات ناقل جين للخلايا والأعضاء والأنسجة
HU229805B1 (en) Photochemical internalization for delivery of molecules into the cytosol
Keogh et al. High efficiency reporter gene transfection of vascular tissue in vitro and in vivo using a cationic lipid–DNA complex
Cortes et al. Successful use of a plant gene in the treatment of cancer in vivo
Tan et al. TRANSFERRIN RECEPTOR-MEDIATED GENE TRANSFER TO THE CORNEAL ENDOTHELIUM1
Kim et al. Implications of nasopharynx‐associated lymphoid tissue (NALT) in the development of allergic responses in an allergic rhinitis mouse model
Greenberger et al. Modulation of redox signal transduction pathways in the treatment of cancer
CN102202693A (zh) 截短型eif-5a1多核苷酸诱导癌细胞凋亡的用途
van de Water et al. Gene therapy in the inner ear: mechanisms and clinical implications
Reinblatt et al. Utilizing tumor hypoxia to enhance oncolytic viral therapy in colorectal metastases
Sands et al. Gene therapy for murine mucopolysaccharidosis type VII
CN101443047A (zh) 在哺乳动物细胞中Li表达的抑制作用
Shibata et al. Massive apoptotic cell death in chemically induced rat urinary bladder carcinomas following in situ HSVtk electrogene transfer
Pap et al. Gene transfer: from concept to therapy
Wang et al. Enhancing cell viability and efficiency of plasmid DNA electrotransfer through reducing plasma membrane permeabilization

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20110810

Termination date: 20141029

EXPY Termination of patent right or utility model